European Journal of Breast Health

EDITORIALS
Early Surgery in De Novo MBC
Soran et al.; On behalf of The Breast Disease Working Group

Daraï et al.; Paris, Strasbourg, France

ORIGINAL ARTICLES
BIA-ALCL after Gender Reassignment Surgery
Zaveri et al; NY, USA

Comparison Bolus Materials in Radiotherapy
Aras et al; Istanbul, Turkey

Ultrasound-Guided Biopsy of Breast Lesions
Okoli et al; Nnewi, Nigeria

The Effect of Systemic Chemotherapy
Çelebi et al; Istanbul, Turkey

Men’s Attitudes Towards Breast
Ozaydın et al; Istanbul, Turkey

Axillary Involvement in Early Stage Breast Cancer Patients
Ataş et al; Ankara, Turkey

Does Gross Martin Examination Reduce Re-excision Rate in Breast Conservation for Invasive Carcinoma?
Hoekstra et al; Portland, ME, Boston, MA, USA

Strategies of Male Breast Cancer Management
Liu et al; Columbus, OH, USA

Breast Cancer in Patients 80 Years-Old and Older
Bertolo et al; Ontario, Canada

Editor-in Chief
Vahit ÖZMEN, Turkey

Editor
Atilla SORAN, USA
Editorial Advisory Board

Alexandru Eniu
Cancer Institute, Cluj-Napoca, Romania

Ayşegül Şahin
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Barbara Lynn Smith
Massachusetts General Hospital, Boston, MA, USA

Bekir Kuru
Ondokuz Mayıs University School of Medicine, Samsun, Turkey

Bolivar Arboleda
HIMA San Pablo Breast Institute-Caguas, Puerto Rico, USA

David Atallah
Department of Obstetrics and Gynecology, Hotel Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon

Edward Sauter
Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Maryland, USA

Eisuke Fukuma
Breast Center, Kameda Medical Center, Kamogawa, Chiba, Japan

Eli Avisar
Division of Surgical Oncology, Miller School of Medicine University of Miami, Florida, USA

Hasan Karanlık
İstanbul University Oncology Institute, İstanbul, Turkey

Hideko Yamauchi
St. Luke’s International Hospital, Tokyo, Japan

Jeffrey Falk
St. John Hospitaland Medical Center, Detroit, MI, USA

John R. Keyserlingk
Medical Director, Surgical Oncologist, VM Medical, Montreal, Canada

Jules Sumkin
Department of Radiology, University of Pittsburgh, USA

Kandace McGuire
VCU School of Medicine, VCU Massey Cancer Center, Richmond, VA, USA

Kevin S. Hughes
Harvard Medical School, Boston, MA, USA

Leonardo Novais Dias
Fellowship in Breast Surgery in European Institute of Oncology and Champalimaud Foundation, Lisbon, Portugal

Lisa A. Newman
University of Michigan, Comprehensive Cancer Center, Michigan, USA

Luiz Henrique Gebrim
Department of Mastology, Federal University of Sao Paulo, Sao Paulo, Brazil

Maurício Magalhães Costa
Americas Medical City Breast Center, Rio de Jeneiro, Brasil

Naim Kadoglu
London North West Healthcare NHS Trust, Ealing Hospital, London, UK

Neslihan Cabioğlu
İstanbul University İstanbul School of Medicine, İstanbul, Turkey

Ronald Johnson
University of Pittsburgh, Magee-Womens Hospital, Pittsburgh, PA, USA

Schlomo Schneebaum
Department of Surgery, Breast Health Center, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Seher Demirer
Ankara University School of Medicine, Ankara, Turkey

Seigo Nakamura
Showa University School of Medicine, Tokyo, Japan

Stanley N C Anyanwu
Nnamdi Azikiwe University, Teaching Hospital, Nnewi, Nigeria

Tadeusz Pienkowski
Medical University of Gdansk, Gdansk, Poland
European Journal of Breast Health (Eur J Breast Health) is an international, scientific, open access periodical published by independent, unbiased, and double-blinded peer-review principles. It is the official publication of the Turkish Federation of Breast Diseases Societies, and Senologic International Society is the official supporter of the journal.

European Journal of Breast Health is published quarterly in January, April, July, and October. The publication language of the journal is English.

EJBH aims to be comprehensive, multidisciplinary source and contribute to the literature by publishing manuscripts with the highest scientific level in the fields of research, diagnosis, and treatment of all breast diseases; scientific, biologic, social and psychological considerations, news and technologies concerning the breast, breast care and breast diseases.

The journal publishes; original research articles, case reports, reviews, letters to the editor, brief correspondences, meeting reports, editorial summaries, observations, novel ideas, basic and translational research studies, clinical and epidemiological studies, treatment guidelines, expert opinions, commentaries, clinical trials and outcome studies on breast health, biology and all kinds of breast diseases that are prepared and presented according to the ethical guidelines.

TOPICS within the SCOPE of EJBH concerning the breast health, breast biology and all kinds of breast diseases:

The target audience of the journal includes specialists and medical professionals in general surgery and breast diseases.

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Committee of Medical Journal Editors (ICMJE), World Association of Medical Editors (WAME), Council of Science Editors (CSE), Committee on Publication Ethics (COPE), European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal is in conformity with the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).

European Journal of Breast Health indexed in PubMed Central, Web of Science-Emerging Sources Citation Index, TUBITAK ULAKBIM TR Index, Embase, EBSCO, CINAHL.

Processing and publication are free of charge with the journal. No fees are requested from the authors at any point throughout the evaluation and publication process. All manuscripts must be submitted via the online submission system, which is available at www.eurjbreasthealth.com. The journal guidelines, technical information, and the required forms are available on the journal’s web page.

All expenses of the journal are covered by the Turkish Federation of Breast Diseases Societies. All expenses of the journal are covered by the Turkish Federation of Breast Diseases Societies. Potential advertisers should contact the Editorial Office. Advertisement images are published only upon the Editor-in-Chief’s approval.

Statements or opinions expressed in the manuscripts published in the journal reflect the views of the author(s) and not the opinions of the Turkish Federation of Breast Diseases Societies, editors, editorial board, and/or publisher; the editors, editorial board, and publisher disclaim any responsibility or liability for such materials.

All published content is available online, free of charge at www.eurjbreasthealth.com.

Turkish Federation of Breast Diseases Societies holds the international copyright of all the content published in the journal.

Editor-in-Chief: Prof. Vahit ÖZMEN
Address: Department of General Surgery, Istanbul University Istanbul Faculty of Medicine, Çapa, Istanbul
Phone: +90 (212) 534 02 10
Fax: +90 (212) 534 02 10
E-mail: editor@eurjbreasthealth.com
Web: eurjbreasthealth.com

Publisher: AVES
Address: Büyükdere Cad., 105/9 34394 Mecidiyeköy, Şişli, Istanbul, Turkey
Phone: +90 212 217 17 00
Fax: +90 212 217 22 92
E-mail: info@avesyayincilik.com
Web page: avesyayincilik.com
European Journal of Breast Health (Eur J Breast Health) is an international, open access, online-only periodical published in accordance with the principles of independent, unbiased, and double-blinded peer-review.

The journal is owned by Turkish Federation of Breast Diseases Societies and it is published quarterly on January, April, July, and October. The publication language of the journal is English. The target audience of the journal includes specialists and medical professionals in general surgery and breast diseases.

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).

Originality, high scientific quality, and citation potential are the most important criteria for a manuscript to be accepted for publication. Manuscripts submitted for evaluation should not have been previously presented or already published in an electronic or printed medium. The journal should be informed of manuscripts that have been submitted to another journal for evaluation and rejected for publication. The submission of previous reviewer reports will expedite the evaluation process. Manuscripts that have been presented in a meeting should be submitted with detailed information on the organization, including the name, date, and location of the organization.

Manuscripts submitted to the Journal of Breast Health will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in their fields in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions.

An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki “Ethical Principles for Medical Research Involving Human Subjects,” amended in October 2013. www.wma.net) is required for experimental, clinical, and drug studies and for some case reports. If required, ethics committee reports or an equivalent official document will be requested from the authors. For manuscripts concerning experimental research on humans, a statement should be included that shows that written informed consent of patients and volunteers was obtained following a detailed explanation of the procedures that they may undergo. For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. Information on patient consent, the name of the ethics committee, and the ethics committee approval number should also be stated in the Materials and Methods section of the manuscript. It is the authors’ responsibility to carefully protect the patients’ anonymity. For photographs that may reveal the identity of the patients, signed releases of the patient or responsible to carefully protect the patients’ anonymity. For photographs that may reveal the identity of the patients, signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient or signed releases of the patient.

All submissions are screened by a similarity detection software (iThenticate by CrossCheck).

In the event of alleged or suspected research misconduct, e.g., plagiarism, citation manipulation, and data falsification/fabrication, the Editorial Board will follow and act in accordance with COPE guidelines.

Each individual listed as an author should fulfill the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE - www.icmje.org). The ICMJE recommends that authorship be based on the following 4 criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he/she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

All those designated as authors should meet all four criteria for authorship, and the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged in the title page of the manuscript.

Journal of Breast Health requires corresponding authors to submit a signed and scanned version of the authorship contribution form (available for download through www.eurjbreasthealth.com) during the initial submission process in order to act appropriately on authorship rights and to prevent ghost or honorary authorship. If the editorial board suspects a case of “gift authorship,” the submission will be rejected without further review. As part of the submission of the manuscript, the corresponding author should also send a short statement declaring that he/she accepts to undertake all the responsibility for authorship during the submission and review stages of the manuscript.

Journal of Breast Health requires and encourages the authors and the individuals involved in the evaluation process of submitted manuscripts to disclose any existing or potential conflicts of interests, including financial, consultant, and institutional, that might lead to potential bias or a conflict of interest. Any financial grants or other support received for a submitted study from individuals or institutions should be disclosed to the Editorial Board. To disclose a potential conflict of interest, the ICMJE Potential Conflict of Interest Disclosure Form should be filled in and submitted by all contributing authors. Cases of a potential conflict of interest of the editors, authors, or reviewers are resolved by the Journal’s Editorial Board within the scope of COPE and ICMJE guidelines.

The Editorial Board of the Journal handles all appeal and complaint cases within the scope of COPE guidelines. In such cases, authors should get in direct contact with the editorial office regarding their appeals and complaints. When needed, an ombudsperson may be assigned to resolve cases that cannot be resolved internally. The Editor in Chief is the final authority in the decision-making process for all appeals and complaints.

When submitting a manuscript to the Journal of Breast Health, authors accept to assign the copyright of their manuscript to Turkish Federation of Breast Diseases Societies. If rejected for publication, the copyright of the manuscript will be assigned back to the authors. European Journal of Breast Health requires each submission to be accompanied by a Copyright Transfer Form (available for download at www.eurjbreasthealth.com). When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Statements or opinions expressed in the manuscripts published in the Journal of Breast Health reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility in regard to the published content rests with the authors.

MANUSCRIPT PREPARATION

The manuscripts should be prepared in accordance with ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in December 2019 - http://www.icmje.org/icmje-recommendations.pdf). Authors are required to prepare manuscripts in accordance with the CONSORT guidelines for randomized research studies, STROBE guidelines for observational original research studies, and to disclose any existing or potential conflicts of interests, including financial, consultant, and institutional, that might lead to potential bias or a conflict of interest. Any financial grants or other support received for a submitted study from individuals or institutions should be disclosed to the Editorial Board. To disclose a potential conflict of interest, the ICMJE Potential Conflict of Interest Disclosure Form should be filled in and submitted by all contributing authors.
Instructions to Authors

STARD guidelines for studies on diagnostic accuracy, PRISMA guidelines for systematic reviews and meta-analysis, ARRIVE guidelines for experimental animal studies, and TREND guidelines for non-randomized public behavior.

Manuscripts can only be submitted through the journal's online manuscript submission and evaluation system, available at www.eurjbreasthealth.com. Manuscripts submitted via any other medium will not be evaluated.

Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal’s guidelines. Submissions that do not conform to the journal's guidelines will be returned to the submitting author with technical correction requests.

Authors are required to submit the following:

- Copyright Transfer Form,
- Material and Methods Form, and
- ICMJE Potential Conflict of Interest Disclosure Form (should be filled in by all contributing authors) during the initial submission. These forms are available for download at www.eurjbreasthealth.com.

Preparation of the Manuscript

Title page: A separate title page should be submitted with all submissions and this page should include:

- The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
- Name(s), affiliations, and highest academic degree(s) of the author(s),
- Grant information and detailed information on the sources of support,
- Name, address, telephone (including the mobile phone number) and fax numbers, and email address of the corresponding author,
- Acknowledgment of the individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria.

Abstract: An English abstract should be submitted with all submissions except for Letters to the Editor. Submitting a Turkish abstract is not compulsory for international authors. The abstract of Original Articles should be structured with subheadings (Objective, Materials and Methods, Results, and Conclusion). Please check Table 1 below for word count specifications.

Key Points: Each submission must be accompanied by a minimum of three to a maximum of six keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (https://www.nlm.nih.gov/mesh/MBrowser.html).

Key Points: All submissions except letters to the editor should be accompanied by 3 to 5 “key points” which should emphasize the most noteworthy results of the study and underline the principle message that is addressed to the reader. This section should be structured as itemized to give a general overview of the article. Since “Key Points” targeting the experts and specialists of the field, each item should be written as plain and straightforward as possible.

Manuscript Types

Original Articles: This is the most important type of article since it provides new information based on original research. The main text of original articles should be structured with Introduction, Material and Methods, Results, Discussion and Conclusions subheadings. Please check Table 1 for the limitations for Original Articles.

Statistical analysis to support conclusions is usually necessary. Statistical analyses must be conducted in accordance with international statistical reporting standards (Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. Br Med J 1983; 7; 1489-93). Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used during the process must be specified.

Units should be prepared in accordance with the International System of Units (SI).

Editorial Comments: Editorial comments aim to provide a brief critical commentary by reviewers with expertise or with high reputation in the topic of the research article published in the journal. Authors are selected and invited by the journal to provide such comments. Abstract, Keywords, and Tables, Figures, Images, and other media are not included.

Review Articles: Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed. These authors may even be invited by the journal. Reviews should describe, discuss, and evaluate the current level of knowledge of a topic in clinical practice and should guide future studies. The main text should contain Introduction, Clinical and Research Consequences, and Conclusion sections. Please check Table 1 for the limitations for Review Articles.

Case Reports: There is limited space for case reports in the journal and reports on rare cases or conditions that constitute challenges in diagnosis and treatment, those offering new therapies or revealing knowledge not included in the literature, and interesting and educative case reports are accepted for publication. The text should include Introduction, Case Presentation, Discussion, and Conclusion subheadings. Please check Table 1 for the limitations for Case Reports.

Letters to the Editor: This type of manuscript discusses important parts, overlooked aspects, or lacking parts of a previously published article. Articles on subjects within the scope of the journal that might attract the readers’ attention, particularly educative cases, may also be submitted in the form of a “Letter to the Editor.” Readers can also present their comments on the published manuscripts in the form of a “Letter to the Editor.” Abstract, Keywords, and Tables, Figures, Images, and other media should not be included. The text should be unstructured. The manuscript that is being commented on must be properly cited within this manuscript.

Images in Clinical Practices: Our journal accepts original high quality images related to the cases that we come across during clinical practices, that cite the importance or infrequency of the topic, make the visual quality stand out and present important information that should be shared in academic platforms. Titles of the images should not exceed 10 words. Images can be signed by no more than 3 authors. Figure legends are limited to 200 words and the number of figures is limited to 3. Video submissions will not be considered.

Current Opinion: Current Opinion provides readers with a commentary of either recently published articles in the European Journal of Breast Health or some other hot topic selected articles. Authors are selected and invited by the journal for such commentaries. This type of article contains three main sections titled as Background, Present Study, and Implications. Authors are expected to turn their recent research to the Editor, and the journal will turn to the submitting author with technical correction requests.

Table 1. Limitations for each manuscript type

<table>
<thead>
<tr>
<th>Type of manuscript</th>
<th>Word limit</th>
<th>Abstract word limit</th>
<th>Reference limit</th>
<th>Table limit</th>
<th>Figure limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Article</td>
<td>3500</td>
<td>250 (Structured)</td>
<td>30</td>
<td>6</td>
<td>7 or total of 15 images</td>
</tr>
<tr>
<td>Review Article</td>
<td>5000</td>
<td>250</td>
<td>50</td>
<td>6</td>
<td>10 or total of 20 images</td>
</tr>
<tr>
<td>Case Report</td>
<td>1000</td>
<td>200</td>
<td>15</td>
<td>No tables</td>
<td>10 or total of 20 images</td>
</tr>
<tr>
<td>Letter to the Editor</td>
<td>500</td>
<td>No abstract</td>
<td>5</td>
<td>No tables</td>
<td>No media</td>
</tr>
<tr>
<td>Current Opinion</td>
<td>300</td>
<td>No abstract</td>
<td>5</td>
<td>No tables</td>
<td>No media</td>
</tr>
</tbody>
</table>

BR-IADS: Breast imaging, report and data systems
describe the background of the subject/study briefly, critically discuss the present research, and provide insights for future studies.

Tables
Tables should be included in the main document, presented after the reference list, and they should be numbered consecutively in the order they are referred to within the main text. A descriptive title must be placed above the tables. Abbreviations used in the tables should be defined below the tables by footnotes (even if they are defined within the main text). Tables should be created using the "insert table" command of the word processing software and they should be arranged clearly to provide easy reading. Data presented in the tables should not be a repetition of the data presented within the main text but should be supporting the main text.

Figures and Figure Legends
Figures, graphics, and photographs should be submitted as separate files (in TIFF or JPEG format) through the submission system. The files should not be embedded in a Word document or the main document. When there are figure subunits, the subunits should not be merged to form a single image. Each subunit should be submitted separately through the submission system. Images should not be labeled (a, b, c, etc) to indicate figure subunits. Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends. Like the rest of the submission, the figures too should be blinded. Any information within the images that may indicate an individual or institution should be blinded. The minimum resolution of each submitted figure should be 300 DPI. To prevent delays in the evaluation process, all submitted figures should be clear in resolution and large in size (minimum dimensions: 100 × 100 mm). Figure legends should be listed at the end of the main document.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition.

When a drug, product, hardware, or software program is mentioned within the main text, product information, including the name of the product, the producer of the product, and city and the country of the company (including the state if in USA), should be provided in parentheses in the following format: "Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)"

All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively in the order they are referred to within the main text.

Limitations, drawbacks, and the shortcomings of original articles should be mentioned in the Discussion section before the conclusion paragraph.

References
While citing publications, preference should be given to the latest, most up-to-date publications. If an ahead-of-print publication is cited, the DOI number should be provided. Authors are responsible for the accuracy of references. Journal titles should be abbreviated in accordance with the journal abbreviations in Index Medicus/ MEDLINE/PubMed. When there are six or fewer authors, all authors should be listed. If there are seven or more authors, the first six authors should be listed followed by "et al." In the main text of the manuscript, references should be cited using Arabic numbers in parentheses. References published in PubMed should have a PMID: xxxxxx at the end of the reference. All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition.

When a drug, product, hardware, or software program is mentioned within the main text, product information, including the name of the product, the producer of the product, and city and the country of the company (including the state if in USA), should be provided in parentheses in the following format: "Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)"

All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively in the order they are referred to within the main text.

Limitations, drawbacks, and the shortcomings of original articles should be mentioned in the Discussion section before the conclusion paragraph.

REVISIONS
When submitting a revised version of a paper, the author must submit a detailed "Response to the reviewers" that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer’s comment, followed by the author’s reply and line numbers where the changes have been made) as well as an annotated copy of the main document. Revised manuscripts must be submitted within 30 days from the date of the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request this extension before the initial 30-day period is over.

Accepted manuscripts are copy-edited for grammar, punctuation, and format. Once the publication process of a manuscript is completed, it is published online on the journal’s webpage as an ahead-of-print publication before it is included in its scheduled issue. A PDF proof of the accepted manuscript is sent to the corresponding author and their publication approval is requested within 2 days of their receipt of the proof.
EDITORIALS

158 Loco-Regional Treatment for Intact Primary Tumor in Patient with De Novo Metastatic Breast Cancer; Comments and Concerns of ECOG-ACRIN 2108 Trial
Atilla Soran, Serdar Özdut, Lütfi Doğan, Efe Sezgin, Vahtı Özmé, Sushil Beriwal, Adam Brufsley

160 Breast Cancer Management during the COVID 19 Pandemic: French Guidelines
Emile Daral, Carole Mathelin, Joseph Gligorov

REVIEW

162 Breast Implant-Associated Anaplastic Large Cell Lymphoma Following Gender Reassignment Surgery: A Review of Presentation, Management, and Outcomes in the Transgender Patient Population
Shruti Zaver, Alice Yao, Hank Schmidt

ORIGINAL ARTICLES

167 Dosimetric Comparison of Superflab and Specially Prepared Bolus Materials Used in Radiotherapy Practice
Serhat Aras, İhsan Oğuz Tanzer, Türkan İkizceli

171 Ultrasound-Guided Core Biopsy of Breast Lesions in a Resource Limited Setting: Initial Experience of a Multidisciplinary Team
Chinedu Okoli, Uzoamaka Ebubedike, Stanley Anyanwu, Gabriel Chianakwana, Chinemelum Emegokor, Cornelius Ukah, Eric Umeh, Micheal Onwukamuche, Ochonma Egwuonwu, Eric Ihekwoaba

177 The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial
Filiz Celebi, Çetin Ordu, Serkan Ilgün, Alper Öztürk, Zeynep Erdoğan Iyigün, Gül Alço, Tomris Duymaz, Fatma Aktepe, Gürsel Soybir, Bülent Baysal, Vahtı Özmé

183 Men’s Knowledge and Attitudes Towards Breast Cancer: A Descriptive Study
Ayşe Nilüfer Özyayın, Emrah Doğan, Berk Bozdoğan

192 Associated Features with Non-Sentinel Lymph Node Involvement in Early Stage Breast Cancer Patients who Have Positive Macrometastatic Sentinel Lymph Node
Hakan Ataş, Bukelet Altoz Ozmér, Ebru Menekşe, Sabri Özdén, Yunus Nadi Yüsük, Gül Dağlar

198 Does Gross Margin Examination Reduce Re-excision Rate in Breast Conservation for Invasive Carcinoma? CALLER Review
Suzanne Hoekstra, Diane Stoller, Haya Raef

201 Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls
Joseph Liu, Anupama Suresh, Marilly Paletas, Julie Stephens, Akaansha Ganju, Evan Morgan, Mahmoud Kassem, Yanjun Hou, Anil Parwani, Anne Noonan, Raquel Reinbolt, Jeffrey VanDeusen, Sagar Sardessa, Nicole Williams, Mathew Cherian, Gary Tozbikian, Daniel G. Stover, Maryam Lustberg, Zaibo Li, Bhuvaneswari Ramaswamy, Robert Wesolowski

208 Breast Cancer in Patients 80 Years-Old and Older
Aaron Bertolo, Christopher Rosso, Ioannis A. Voutsadakis

213 Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR
Ramesh Omranipour, Roghieh Jallil, Adel Yazdankohkenany, Abdolali Assarian, Mehrad Mirzania, Bita Eslami

219 Pre-Treatment and Post-Treatment Anxiety, Depression, Sleep and Sexual Function Levels in Patients with Breast Cancer
Filiz İzcı, Gözdem Özdem, Ahmet Serkan Ilgün, Filiz Ağacayak, Tomris Duymaz, Zeynep Erdoğan, Gül Alço, Filiz Elbükên, Alper Öztürk, Çetin Ordu, Kübra Ceren Ateşal, Özge İpek Doğan, Fatma Aktepe, Vahtı Özmé

LETTER TO THE EDITOR

226 The Predictive Value of the Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio in Patients with Recurrent Idiopathic Granulomatous Mastitis
Sami Akbulut, Tevfik Tolga Şahıın

ERRATUM

A-VII